Business
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\n Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company\n pioneering a new way to treat the underlying cause of severe genetic\n diseases by precisely upregulating protein expression, today\n announced that Chief Executive Officer Edward M. Kaye, M.D., will\n present at the 38th Annual J.P. Morgan Healthcare Conference\n on Tuesday, January 14, 2020 at 2:30 p.m. PT (5:30 p.m. ET) in San\n Francisco.\n \n \n A live audio webcast of the presentation will be available on the\n Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/.\n A replay of the webcast will be available for 30 days following the\n presentations.\n \n \n About Stoke TherapeuticsStoke Therapeutics,\n Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to\n treat the underlying causes of severe genetic diseases by precisely\n upregulating protein expression to restore target proteins to near\n normal levels. Stoke aims to develop the first precision medicine\n platform to target the underlying cause of a broad spectrum of genetic\n diseases in which the patient has one healthy copy of a gene and one\n mutated copy that fails to produce a protein essential to health. These\n diseases, in which loss of approximately 50% of normal protein\n expression causes disease, are called autosomal dominant\n haploinsufficiencies. The company’s lead investigational new medicine is\n STK-001, a proprietary antisense oligonucleotide (ASO) that has the\n potential to be the first disease-modifying therapy to address the\n genetic cause of Dravet syndrome, a severe and progressive genetic\n epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices\n in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or\n follow the company on Twitter at @StokeTx.\n \n \n \n View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005163/en/\n\n \n Stoke Media & Investor Contact:Dawn KalmarVice\n President, Head of Corporate [email protected]\n \n \n \n\nSource: Stoke Therapeutics, Inc.","length":4223,"tagName":"div"}]